Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00507585 · ClinicalTrials.gov registry record · Phase 1
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT00507585: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00507585 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00507585, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
PRIMARY: * To determine the toxicity and tolerability of intra-arterial hepatic oxaliplatin every three weeks administered in combination with systemic intravenous Fluorouracil, Leucovorin and bevacizumab to patients with advanced solid tumors metastatic to the liver. SECONDARY: * To document in a descriptive fashion the antitumor efficacy of this combination regimen. * To evaluate the feasibility and accuracy of an alternate radiographic assessment tool and compare with available tumor markers and RECIST guidelines. * To estimate in a descriptive fashion the development of extrahepatic tumor recurrences.
Interventions
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00507585
The ClinicalTrials.gov registry entry for NCT00507585 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluorouracil is the first listed.
NCT00507585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00507585 about?
NCT00507585 is a clinical study titled "Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin". PRIMARY: * To determine the toxicity and tolerability of intra-arterial hepatic oxaliplatin every three weeks administered in combination with systemic intravenous Fluorouracil, Leucovorin and bevacizumab to patients with advanced solid tumors metastatic to the liver. SECONDARY: * To document in ...
What is the current status of trial NCT00507585?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2006-06. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00507585?
The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), Avastin (DRUG).
Who is sponsoring clinical trial NCT00507585?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.